Contrary to TGF-β3 immunoreactivity, which was detectable in normal as well as grade I and grade II samples but not in grade III samples [6], TGF-β1 and TGF-β2 immunoreactivity was detectable throughout cancer progression, even in grade III tumours (Figure 1A). This evidence concerns the gene TGFB3 and neoplasm.